UK markets open in 3 hours 31 minutes

Dechra Pharmaceuticals plc (DPH.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
2,796.00+22.00 (+0.79%)
At close: 06:28PM GMT
Currency in GBp

Valuation measures4

Market cap (intra-day) 3.09B
Enterprise value 3.30B
Trailing P/E 50.82
Forward P/E 22.94
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.34
Price/book (mrq)4.63
Enterprise value/revenue 4.84
Enterprise value/EBITDA 18.43

Trading information

Stock price history

Beta (5Y monthly) 0.66
52-week change 3-31.67%
S&P500 52-week change 3-8.38%
52-week high 34,366.00
52-week low 30.00
50-day moving average 32,720.28
200-day moving average 33,104.57

Share statistics

Avg vol (3-month) 3419.42k
Avg vol (10-day) 3470.79k
Shares outstanding 5113.84M
Implied shares outstanding 6N/A
Float 8107.83M
% held by insiders 10.88%
% held by institutions 165.58%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.45
Forward annual dividend yield 41.62%
Trailing annual dividend rate 30.45
Trailing annual dividend yield 30.02%
5-year average dividend yield 41.04
Payout ratio 477.51%
Dividend date 3N/A
Ex-dividend date 427 Oct 2022
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Jun 2022
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin 8.54%
Operating margin (ttm)14.05%

Management effectiveness

Return on assets (ttm)4.78%
Return on equity (ttm)8.96%

Income statement

Revenue (ttm)681.8M
Revenue per share (ttm)6.29
Quarterly revenue growth (yoy)13.40%
Gross profit (ttm)384.8M
EBITDA 139.2M
Net income avi to common (ttm)58.2M
Diluted EPS (ttm)0.53
Quarterly earnings growth (yoy)-45.70%

Balance sheet

Total cash (mrq)120.9M
Total cash per share (mrq)1.12
Total debt (mrq)329.1M
Total debt/equity (mrq)49.35
Current ratio (mrq)2.80
Book value per share (mrq)6.15

Cash flow statement

Operating cash flow (ttm)122.9M
Levered free cash flow (ttm)23.88M